Search

Displaying results 8471 - 8480 of 10000 in total
  1. Pathway

    Cardiolipin Biosynthesis CL(20:3(11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(11Z,14Z,17Z))

    smpdb.ca/view/SMP0253858
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  2. Pathway

    Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))

    smpdb.ca/view/SMP0254022
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  3. Pathway

    Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))

    smpdb.ca/view/SMP0254949
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  4. Pathway

    Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/20:3(11Z,14Z,17Z))

    smpdb.ca/view/SMP0254962
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  5. Pathway

    Cardiolipin Biosynthesis CL(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(11Z,14Z,17Z)/20:3(11Z,14Z,17Z))

    smpdb.ca/view/SMP0255095
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  6. Pathway

    Cardiolipin Biosynthesis CL(20:2(11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))

    smpdb.ca/view/SMP0256157
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  7. Pathway

    Cardiolipin Biosynthesis CL(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z)/20:3(11Z,14Z,17Z))

    smpdb.ca/view/SMP0287434
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  8. Drug

    Desoxycorticosterone pivalate

    go.drugbank.com/drugs/DB01134
    ExperimentalVet approved

    Desoxycorticosterone pivalate is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air. It is practically insoluble in water, sparingly soluble in acetone, slightly soluble in methano...

    International brands: Cortexone M, Percorten M
  9. Target

    Dihydrolipoyl dehydrogenase

    go.drugbank.com/bio_entities/BE0002616
    TargetPseudomonas putida

    The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2).

    Synonyms: E3 component of branched-chain alpha-keto acid dehydrogenase complex
  10. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A.